150917 AV Basel Presentation
... market potential of our product candidates, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly filings and annual reports. Forward-looking stat ...
... market potential of our product candidates, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly filings and annual reports. Forward-looking stat ...
Enhancement of psychostimulant effect and development of
... unknown way and it is highly probable that its ability to interfere with changes in the brain depends on all of these (Gouliaev & Senning 1994). Certainly more research on this topic will be needed. Possible efficacy of piracetam for the treatment of cocaine dependence in human abusers was tested in ...
... unknown way and it is highly probable that its ability to interfere with changes in the brain depends on all of these (Gouliaev & Senning 1994). Certainly more research on this topic will be needed. Possible efficacy of piracetam for the treatment of cocaine dependence in human abusers was tested in ...
Systematic reviews
... 100 mg kg−1 day−1or placebo rectally, in addition to a morphine loading dose of 100 µg kg−1 and 5–10 µg kg−1 h−1 continuous infusion. Analgesic efficacy was assessed using Visual Analogue Scale (VAS) and COMFORT scores. Extra morphine was administered if VAS was ≥4. Results We analysed data of 54 pa ...
... 100 mg kg−1 day−1or placebo rectally, in addition to a morphine loading dose of 100 µg kg−1 and 5–10 µg kg−1 h−1 continuous infusion. Analgesic efficacy was assessed using Visual Analogue Scale (VAS) and COMFORT scores. Extra morphine was administered if VAS was ≥4. Results We analysed data of 54 pa ...
Gastrokinetic and Gastroprotective Activity of Gasex
... Present study was aimed to evaluate the gastrokinetic and gastroprotective effect of Gasex a polyherbal formulation in experimental models of phenol red test meal method for gastrokinetic activity and acid-induced gastrointestinal lesions for gastroprotective activity. Gasex at a dose of 500 and 100 ...
... Present study was aimed to evaluate the gastrokinetic and gastroprotective effect of Gasex a polyherbal formulation in experimental models of phenol red test meal method for gastrokinetic activity and acid-induced gastrointestinal lesions for gastroprotective activity. Gasex at a dose of 500 and 100 ...
VAGINAL BLEEDING AFTER USE OF SINGLE DOSE ORAL
... Misoprostol is a synthetic prostaglandin E1 analogue. It can be used in both gastroenterological and obstetrical and gynecological conditions. In gastroenterology use, misoprostol therapy is indicated in patients who have duodenal or gastric ulcer due to use of non-steroidal anti-inflammatory drugs ...
... Misoprostol is a synthetic prostaglandin E1 analogue. It can be used in both gastroenterological and obstetrical and gynecological conditions. In gastroenterology use, misoprostol therapy is indicated in patients who have duodenal or gastric ulcer due to use of non-steroidal anti-inflammatory drugs ...
Antimicrobial Use in Mare Reproduction Kristina Lu VMD, DACT
... intrauterine infusion has been associated with shorter duration histologic inflammation though more cellular changes were seen with scanning electron microscopy compared to saline controls. It is generally recommended that gentamicin be buffered or well diluted in saline to minimize irritation. Puru ...
... intrauterine infusion has been associated with shorter duration histologic inflammation though more cellular changes were seen with scanning electron microscopy compared to saline controls. It is generally recommended that gentamicin be buffered or well diluted in saline to minimize irritation. Puru ...
Betamethasone Sodium Phosphate and Betamethasone Acetate
... serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. General Rare instances of anaphylactoid reactions have occurred i ...
... serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. General Rare instances of anaphylactoid reactions have occurred i ...
Challenges and new discoveries in the treatment of
... Amphotericin B (deoxycholate) has been given to large numbers of patients with kala-azar that is clinically resistant to Pentostam and pentamidine. In Bihar, 99% of patients were cured with the standard regimen of 20 injections (1 mg/ kg/AD) of amphotericin B. Further studies showed that the duratio ...
... Amphotericin B (deoxycholate) has been given to large numbers of patients with kala-azar that is clinically resistant to Pentostam and pentamidine. In Bihar, 99% of patients were cured with the standard regimen of 20 injections (1 mg/ kg/AD) of amphotericin B. Further studies showed that the duratio ...
Advanced Pharmaceutics
... levels have been shown to significantly increase with therapeutic doses of pentoxifylline in patients with peripheral arterial disease. Mesotherapists believe that by increasing microcirculation of localized tissue beds, the elimination of metabolic waste is facilitated. Injecting pentoxifyllinemeso ...
... levels have been shown to significantly increase with therapeutic doses of pentoxifylline in patients with peripheral arterial disease. Mesotherapists believe that by increasing microcirculation of localized tissue beds, the elimination of metabolic waste is facilitated. Injecting pentoxifyllinemeso ...
Overview of 2013 American College of Cardiology/American Heart
... Statins have an excellent margin of safety in properly selected patients who are appropriately monitored Statins have an excellent safety record in RCTs, where the inclusion and exclusion criteria enhanced safety. Individuals with an increased risk of statin adverse effects (age >75 years, a history ...
... Statins have an excellent margin of safety in properly selected patients who are appropriately monitored Statins have an excellent safety record in RCTs, where the inclusion and exclusion criteria enhanced safety. Individuals with an increased risk of statin adverse effects (age >75 years, a history ...
Acetazolamide: Considerations for Systemic Administration
... the high number of carbonic anhydrase enzymes in the kidneys; this may require very high doses of the drug to be effective, which also exposes the patient to greater risk of adverse effects. Moreover, some patients develop drug tolerance, which may occur after taking the medication for one to six mo ...
... the high number of carbonic anhydrase enzymes in the kidneys; this may require very high doses of the drug to be effective, which also exposes the patient to greater risk of adverse effects. Moreover, some patients develop drug tolerance, which may occur after taking the medication for one to six mo ...
Flixonase
... Under normal circumstances, very low plasma concentrations of fluticasone propionate are achieved after intranasal dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 3A4 in the gut and liver. Hence, clinically significant drug interactions mediated ...
... Under normal circumstances, very low plasma concentrations of fluticasone propionate are achieved after intranasal dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 3A4 in the gut and liver. Hence, clinically significant drug interactions mediated ...
Treatment options for the Opioid Dependent Patient
... ≥ 3 of the following occurring in the same 12- month period 1. Desire or unsuccessful efforts to cut down on opiate use 2. Large amount of time spent obtaining opiates, using opiates, or recovering from opiate effects 3. Social, occupational, or recreational activities reduced because of opiate use ...
... ≥ 3 of the following occurring in the same 12- month period 1. Desire or unsuccessful efforts to cut down on opiate use 2. Large amount of time spent obtaining opiates, using opiates, or recovering from opiate effects 3. Social, occupational, or recreational activities reduced because of opiate use ...
November 2014 PBAC Meeting
... Stable disease (SD) is small changes that do not meet above criteria. Note No increase in the maximum number of repeats may be authorised. Note Special Pricing Arrangements apply. ...
... Stable disease (SD) is small changes that do not meet above criteria. Note No increase in the maximum number of repeats may be authorised. Note Special Pricing Arrangements apply. ...
Managing Calcium Channel Blocker
... reporting edema with CCB monotherapy, slightly but not significantly more common in women than men (15.6% vs. 11.8%),1 with the varying prevalence according to the specific agent (Table). Two major hypertension trials involving CCBs have reported edema rates: the second Swedish Trial in Old Patients ...
... reporting edema with CCB monotherapy, slightly but not significantly more common in women than men (15.6% vs. 11.8%),1 with the varying prevalence according to the specific agent (Table). Two major hypertension trials involving CCBs have reported edema rates: the second Swedish Trial in Old Patients ...
0.9% Sodium Chloride Injection, USP
... Clinical studies of 0.9% Sodium Chloride injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in the responses between elderly and younger ...
... Clinical studies of 0.9% Sodium Chloride injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in the responses between elderly and younger ...
LUCENTIS® Is the First Biologic FDA-Approved for the
... Fatal events occurred more frequently in DME patients treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal u ...
... Fatal events occurred more frequently in DME patients treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal u ...
OPIATE ANALGESICS AND ANTAGONISTS
... morphine, main use in anesthesia . • 3. Duration of action very short (t1/2 = 20 min). • 4. Can be given IM, IV, transdemally or via patient controlled infusion system may be given intrathecally ...
... morphine, main use in anesthesia . • 3. Duration of action very short (t1/2 = 20 min). • 4. Can be given IM, IV, transdemally or via patient controlled infusion system may be given intrathecally ...
QA248_4Pyridostigmine_neostigmine_FINAL
... neostigmine can be administered both orally and parenterally.(2-4) For the parenteral route, neostigmine is licensed for the treatment of myasthenia gravis when given subcutaneous (SC) or intramuscular (IM); the intravenous (IV) route is licensed for reversal of non-depolarising neuromuscular blocka ...
... neostigmine can be administered both orally and parenterally.(2-4) For the parenteral route, neostigmine is licensed for the treatment of myasthenia gravis when given subcutaneous (SC) or intramuscular (IM); the intravenous (IV) route is licensed for reversal of non-depolarising neuromuscular blocka ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.